Postpartum thyroiditis risk factors: Difference between revisions
Jump to navigation
Jump to search
Sunny Kumar (talk | contribs) |
Sunny Kumar (talk | contribs) No edit summary |
||
Line 4: | Line 4: | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
The most potent risk factor in the development of PPT are genetic and subsequent pregnancies. Other risk factors include smoking, increase or decreased intake of Iodine, hepatitis C, radiations and medications. | The most potent risk factor in the development of [[Postpartum thyroiditis|postpartum thyroiditis PPT]] are [[Genetics|genetic]] and subsequent pregnancies. Other risk factors include smoking, increase or decreased intake of [[Iodine]], [[hepatitis C]], radiations and medications.<ref name="pmid25507668">{{cite journal| author=Argatska AB, Nonchev BI| title=Postpartum thyroiditis. | journal=Folia Med (Plovdiv) | year= 2014 | volume= 56 | issue= 3 | pages= 145-51 | pmid=25507668 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25507668 }}</ref> | ||
==Risk Factors== | |||
*The most potent risk factor in the development of PPT is genetic. Other risk factors include smoking, increase or decreased intake of Iodine, | *The most potent risk factor in the development of [[Postpartum thyroiditis|PPT]] is [[Genetics|genetic]]. Other risk factors include smoking, increase or decreased intake of [[Iodine]], [[hepatitis C]], radiations and medications. | ||
===Common Risk Factors=== | ===Common Risk Factors=== | ||
*Common risk factor in the development of PPT is genetic and includes | *Common risk factor in the development of [[Postpartum thyroiditis|PPT]] is [[Genetics|genetic]] and includes | ||
**CD60 CTLA-4 gene | **CD60 CTLA-4 gene | ||
**HLA DR3 antigens halpotypes. | **[[HLA DR3-DQ2|HLA DR3]] antigens halpotypes. | ||
**HLA DR4 antigens halpotypes. | **[[HLA-DR4|HLA DR4]] antigens halpotypes. | ||
**HLA DR5 antigens halpotypes. | **HLA [[HLA-DR5|DR5]] antigens halpotypes. | ||
**Subsequent pregnancies | **Subsequent pregnancies | ||
Line 21: | Line 21: | ||
**Intake of Iodine | **Intake of Iodine | ||
**Radiation | **Radiation | ||
**Medications: lithium, amiodarone, interferon alpha, interleukin 2, and the highly active anti- | **Medications: [[lithium]], [[amiodarone]], [[Interferon alpha|interferon alpha,]] [[interleukin 2]], and the highly active [[HIV AIDS medical therapy|anti-retro-viral therapy]]. | ||
**[[Systemic lupus erythromatosis]] | **[[Systemic lupus erythematosus|Systemic lupus erythromatosis]] | ||
**[[Multiple Sclerosis]] | **[[Multiple Sclerosis]] | ||
**[[Thyroid]] hormone resistance syndrome | **[[Thyroid]] hormone resistance syndrome |
Revision as of 18:06, 13 October 2017
Postpartum thyroiditis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Postpartum thyroiditis risk factors On the Web |
American Roentgen Ray Society Images of Postpartum thyroiditis risk factors |
Risk calculators and risk factors for Postpartum thyroiditis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
The most potent risk factor in the development of postpartum thyroiditis PPT are genetic and subsequent pregnancies. Other risk factors include smoking, increase or decreased intake of Iodine, hepatitis C, radiations and medications.[1]
Risk Factors
- The most potent risk factor in the development of PPT is genetic. Other risk factors include smoking, increase or decreased intake of Iodine, hepatitis C, radiations and medications.
Common Risk Factors
Less Common Risk Factors
- Less common risk factors in the development of PPT are environmental and they include:
- Smoking
- Intake of Iodine
- Radiation
- Medications: lithium, amiodarone, interferon alpha, interleukin 2, and the highly active anti-retro-viral therapy.
- Systemic lupus erythromatosis
- Multiple Sclerosis
- Thyroid hormone resistance syndrome
References
- ↑ Argatska AB, Nonchev BI (2014). "Postpartum thyroiditis". Folia Med (Plovdiv). 56 (3): 145–51. PMID 25507668.